Tweet
Vancouver biotech RepliCel Life Sciences Inc. (OTCBB:REPCF)(CNSX:RP) has received a United States patent for its technology related to hair regeneration, the company announced this morning.
The company’s hair restoration procedure involves taking a small biopsy from the back of a patient’s scalp and preparing populations of “dermal sheath cup cells” that are then used to treat patients with pattern hair loss.
“The allowance of our first U.S. patent is a major achievement for our business as the United States represents the largest current market for hair restoration procedures, conservatively estimated at over $1.3 billion annually,” said David Hall, CEO of RepliCel. “The market for a permanent, non-invasive procedure like RepliCel’s is clearly significant.
“If you factor in the still-untouched market of hair loss in women, the total patients for RepliCel’s treatment would expand even further.”
The company already has patents in Australia and the European Union.
The company’s hair restoration procedure involves taking a small biopsy from the back of a patient’s scalp and preparing populations of “dermal sheath cup cells” that are then used to treat patients with pattern hair loss.
“The allowance of our first U.S. patent is a major achievement for our business as the United States represents the largest current market for hair restoration procedures, conservatively estimated at over $1.3 billion annually,” said David Hall, CEO of RepliCel. “The market for a permanent, non-invasive procedure like RepliCel’s is clearly significant.
“If you factor in the still-untouched market of hair loss in women, the total patients for RepliCel’s treatment would expand even further.”
The company already has patents in Australia and the European Union.
Comment